Sun Pharma Ltd – A shining quarterly performance

Sun Pharma quarterly results

Last Updated: Aug 08, 2022 - 06:42 pm 56.7k Views
Listen icon

Sun Pharma net profits turned around to Rs.1,860 crore from net loss of Rs.-1,320 crore on lower exceptional loss provisions on Taro Pharma lawsuits. Meanwhile, Sun reported 28.13% growth in sales at Rs.9,719 crore. The growth was driven by core pharma growth, low base in Jun20 and higher sales of COVID products. 

 

Sun pharma FY22 Q1 Results

Rs in Crore

Jun-21

Jun-20

YOY

Mar-21

QOQ

Total Income (Rs cr)

₹ 9,718.74

₹ 7,585.25

28.13%

₹ 8,522.98

14.03%

Operating Profit (Rs cr)

₹ 2,317.86

₹ 1,347.59

72.00%

₹ 1,494.95

55.05%

Net Profit (Rs cr)

₹ 1,859.92

₹ -1,319.84

N.A.

₹ 992.55

87.39%

Diluted EPS (Rs)

₹ 6.00

₹ -6.90

 

₹ 3.70

 

OPM

23.85%

17.77%

 

17.54%

 

Net Margins

19.14%

-17.40%

 

11.65%

 


India sales at Sun Pharma were up 39% at Rs.3,384 crore. Among other markets, the US formulations grew at 35%, Emerging Markets at 25% and reset of the world at 35%. R&D investments at Rs.593 crore were 6.1% of sales. As part of the debt reduction program, Sun has cut $765 million of debt in the last 5 quarters with $185 million cut in Jun-21 quarter. Sun launched at total of 13 products in the Indian market during the quarter.

Also Check: Dr. Reddy Labs and Torrent Pharma - Quarterly Results

EBITDA was up 59% at Rs.2,772 crore was up 59% yoy. Taro posted sales of $147 million and net profits of $41 million, showing solid growth in top line and bottom line. The reason for the turnaround in net profits from loss last year was the lower exceptional losses for the Department of Justice order against Taro Pharma. In the Jun-21 quarter, Sun provided just Rs.631 crore against Rs.3,633 crore in the Jun-20 quarter. Net margins at 19.14% were higher 750 bps on sequential basis.

Share Market Today


How do you rate this article?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

378X91-D3

About the Author


Enjoy 0%* Brokerage with 5paisa
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
Trust Fintech IPO Subscribed 108.63 times

Trust Fintech IPO is book-built issue of ₹63.45 crores, consisting entirely of fresh issue shares totalling 62.82 lakh. Trust Fintech IPO commenced its subscription period on March 26, 2024, & concludes today, March 28, 2024.

Aspire & Innovative IPO Subscribed 15.17 times

Aspire & Innovative IPO is a book built issue of Rs 21.97 crores. The issue comprises entirely a fresh issue of 40.68 lakh shares. Aspire & Innovative IPO opens for subscription on March 26, 2024, and closes on March 28, 2024. The allotment for the Aspire & Innovative IPO is expected to be finalized on Monday, April 1, 2024.

Blue Pebble IPO Subscribed 56.32 times

Blue Pebble IPO, valued at ₹18.14 crores, comprises fresh issue of 10.8 lakh shares. Commencing subscription on March 26, 2024, Blue Pebble IPO is set to conclude on March 28, 2024. Allotment process is scheduled to be finalized by Monday, April 1, 2024. Following this, IPO is slated to debut on NSE SME, with tentative listing date of Wednesday, April 3, 2024.